BPI Antikörper

Produktnummer ABIN2191910

Der Maus Monoklonal Anti-BPI-Antikörper wurde für IA validiert. Er ist geeignet, BPI in Proben von Human zu detektieren.

Kurzübersicht für BPI Antikörper (ABIN2191910)

Target: BPI (Bactericidal/Permeability Increasing Protein (BPI))

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser BPI Antikörper ist unkonjugiert

Applikation: Immunoassay (IA)

Klon: 3F9

Produktdetails anti-BPI Antikörper

Sterilität: 0.2 μm filtered

Anwendungsinformationen

Applikationshinweise: The monoclonal antibody 3F9 can be used for immuno assays both as coating and as detector.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Buffer: PBS, containing 0.1 % bovine serum albumin and 0.02 % sodium azide.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C

Informationen zur Lagerung: Product should be stored at 4 °C. Under recommended storage conditions, product is stable for one year.

Haltbarkeit: 12 months

Details zu BPI

Target: BPI (Bactericidal/Permeability Increasing Protein (BPI))

Andere Bezeichnung: Bactericidal Permeability Increasing Protein

Hintergrund: The monoclonal antibody 3F9 reacts specifically with full length human natural and recombinant Bactericidal Permeability Increasing protein (BPI). The antimicrobial protein BPI is a 55 kDa protein found in the primary (azurophilic) granules of human neutrophils and has also been detected on surface of neutrophils, small intestinal and oral epithelial cells. BPI is a bactericidal compound that is present in polymorphonuclear cells (PMN) and in lower levels in the specific granules of eosinophils. BPI possesses high affinity toward the lipid A region of lipopolysaccharides (LPS) that comprise the outer leaflet of the gram-negative bacterial outer membrane. Binding of BPI to the lipid A moiety of LPS exerts multiple anti-infective activities against gram-negative bacteria: 1) cytotoxicity via sequential damage to bacterial outer and inner lipid membranes, 2) neutralization of gram-negative bacterial LPS, 3) opsonization of bacteria to enhance phagocytosis by neutrophils. Airway epithelial cells constitutively express the BPI gene and produce the BPI protein and, therefore, BPI may be a critical determinant in the development of LPS-triggered airways disease. Inflammation induced by LPS possibly contributes to the development of rapid airflow decline, a serious and often fatal complication of hematopoietic cell transplantation. Furthermore, a 21 kDa bioactive recombinant fragment of BPI, rBPI21, was shown to confer a survival advantage against invasive pneumococcal disease by binding to the gram-positive bacterial pathogen, pneumolysin. The monoclonal antibody 3F9 recognizes only free BPI and does not interact with BPI that has formed a complex with LPS.